NovaBay Pharmaceuticals, Inc.
NBY
$0.58
-$0.02-3.33%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 2.42M | 2.39M | 2.62M | 3.72M | 2.47M |
| Total Other Revenue | 17.00K | 13.00K | 7.00K | 11.00K | 10.00K |
| Total Revenue | 2.44M | 2.40M | 2.63M | 3.73M | 2.48M |
| Cost of Revenue | 848.00K | 808.00K | 837.00K | 1.91M | 819.00K |
| Gross Profit | 1.59M | 1.59M | 1.79M | 1.82M | 1.66M |
| SG&A Expenses | 2.65M | 2.64M | 3.35M | 2.61M | 2.36M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.50M | 3.45M | 4.20M | 4.53M | 3.18M |
| Operating Income | -1.06M | -1.05M | -1.57M | -798.00K | -698.00K |
| Income Before Tax | -1.21M | -1.59M | -3.09M | -4.11M | -1.35M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -1.21M | -1.59M | -3.09M | -4.11M | -1.35M |
| Earnings from Discontinued Operations | -- | -- | -124.00K | -- | -404.00K |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1.21M | -1.59M | -3.21M | -4.11M | -1.76M |
| EBIT | -1.06M | -1.05M | -1.57M | -798.00K | -698.00K |
| EBITDA | -1.05M | -1.04M | -1.56M | -748.00K | -685.00K |
| EPS Basic | -0.60 | -1.37 | -5.10 | -46.53 | -13.11 |
| Normalized Basic EPS | -0.20 | -0.81 | -2.03 | -4.93 | -6.31 |
| EPS Diluted | -0.60 | -1.37 | -5.10 | -46.53 | -13.11 |
| Normalized Diluted EPS | -0.20 | -0.81 | -2.03 | -4.93 | -6.31 |
| Average Basic Shares Outstanding | 3.71M | 1.16M | 704.90K | 197.10K | 134.00K |
| Average Diluted Shares Outstanding | 3.71M | 1.16M | 704.90K | 197.10K | 134.00K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
